NCT04991948View on ClinicalTrials.gov

Study of Pembrolizumab Treatment After CYAD-101 With FOLFOX Preconditioning in Metastatic Colorectal Cancer

PHASE1RecruitingINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

November 22, 2021

Primary Completion Date

August 21, 2023

Study Completion Date

May 25, 2038

Conditions
Unresectable Metastatic Colorectal Cancer
Interventions
DRUG

CYAD-101

Allogeneic NKG2D-based CYAD-101 Chimeric antigen Receptor T-cells

DRUG

FOLFOX

5-FU, leucovorin and oxaliplatin

DRUG

Pembrolizumab

Humanized immunoglobulin G4 (IgG4) monoclonal antibody (mAb)

Trial Locations (5)

2650

RECRUITING

UZ Antwerpen, Edegem

3000

RECRUITING

UZ Leuven, Leuven

9000

NOT_YET_RECRUITING

UZ Gent, Ghent

32224

NOT_YET_RECRUITING

Mayo Clinic, Jacksonville

33612

NOT_YET_RECRUITING

Moffit Cancer Center, Tampa

Sponsors

Lead Sponsor

Celyad Oncology SA
All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Celyad Oncology SA

INDUSTRY

NCT04991948 - Study of Pembrolizumab Treatment After CYAD-101 With FOLFOX Preconditioning in Metastatic Colorectal Cancer | Biotech Hunter | Biotech Hunter